Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Mamo, D. Articles by Remington, G. Search for Related Content PubMed Citation Articles by Mamo, D. Articles by Remington, G. Neurotransmitters Atypical Neuroleptics Schizophrenia Spectrum Disorders PET

A PET Study of Dopamine D₂ and Serotonin 5-HT₂ Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone

OBJECTIVE: Ziprasidone is an atypical antipsychotic drug that shows a higher affinity for serotonin 5-HT₂ receptors compared with dopamine D₂ receptors in vitro. The affinity of ziprasidone for these receptors in vivo in patients was examined in a positron emission tomography (PET) study. METHOD: The authors conducted a PET study to evaluate D₂ occupancy (using [¹¹C]raclopride) and 5-HT₂ occupancy (using [¹⁸F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range. PET scanning was done after 3 weeks of administration and at trough plasma levels, i.e., 12–16 hours after the last dose. RESULTS: The mean 5-HT₂ receptor occupancy was significantly higher than the mean D₂ receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively). The estimated plasma ziprasidone concentration associated with 50% maximal 5-HT₂ receptor occupancy was almost four times lower than that for D₂ receptor occupancy. CONCLUSIONS: These data affirm that ziprasidone is similar to other novel antipsychotics in having greater 5-HT₂ than D₂ receptor occupancy at therapeutic doses and suggest that the optimal effective dose of ziprasidone is closer to 120 mg/day than to the lower doses suggested by previous PET studies. The relatively high D₂ receptor occupancy, even at trough plasma levels, suggests that ziprasidone is more similar to risperidone and olanzapine in receptor occupancy profile than to clozapine and quetiapine. Since ziprasidone plasma levels show significant (more than twofold) variation within a single dose cycle, studies that are aimed at peak plasma levels (6 hours after the last dose) and that examine extrastriatal regions are required to fully characterize the in vivo occupancy profile of ziprasidone.

This article has been cited by other articles:

				J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature Schizophr Bull, July 1, 2009; 35(4): 789 - 797. [Abstract] [Full Text] [PDF]

				A. Graff-Guerrero, D. Mamo, C. M. Shammi, R. Mizrahi, H. Marcon, P. Barsoum, P. Rusjan, S. Houle, A. A. Wilson, and S. Kapur The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors: A Positron Emission Tomography Study With [11C]-(+)-PHNO Arch Gen Psychiatry, June 1, 2009; 66(6): 606 - 615. [Abstract] [Full Text] [PDF]

				J. J. Guo, P. E. Keck, H. Li, and N. C. Patel Treatment Costs Related to Bipolar Disorder and Comorbid Conditions Among Medicaid Patients With Bipolar Disorder Psychiatr Serv, August 1, 2007; 58(8): 1073 - 1078. [Abstract] [Full Text] [PDF]

				F. E. Lotrich, R. R. Bies, G. S. Smith, and B. G. Pollock Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies J Psychopharmacol, July 1, 2006; 20(4_suppl): 33 - 40. [Abstract] [PDF]

				G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone Am J Psychiatry, March 1, 2006; 163(3): 396 - 401. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us